AISA-021
Raynaud's Phenomenon in Systemic Sclerosis (Scleroderma)
Key Facts
About Aisa Pharma
Aisa Pharma is a clinical-stage biotech company developing AISA-021, a novel 4th generation dual-channel calcium blocker, for the treatment of Raynaud's phenomenon secondary to systemic sclerosis, a severe autoimmune disease with high unmet need. The company has completed Part 1 of its Phase 2 RECONNOITER-1 study in Australia and is nearing completion of Part 2, with encouraging preliminary clinical data suggesting effects on both Raynaud's and underlying disease symptoms. Founded in 2018 by CEO Andrew Sternlicht, M.D., the company leverages a team with extensive drug development experience and a strategy of repurposing known drug classes to improve efficacy and tolerability for underserved patient populations.
View full company profile